Relationship Between Mutant KRAS and ACLS3 Opens Door to Therapy Development for NSCLC

Share this content:
Research has uncovered a potential treatment target for mutant KRAS non-small cell lung cancer: Acyl-Coenzyme A synthetase long chain family member 3.
Research has uncovered a potential treatment target for mutant KRAS non-small cell lung cancer: Acyl-Coenzyme A synthetase long chain family member 3.

New research has uncovered a potential treatment target for mutant KRAS non-small cell lung cancer (NSCLC): Acyl-Coenzyme A synthetase long chain family member 3 (ACLS3).1

ACLS3 belongs to a family of enzymes critical to fatty acid (FA) metabolism, which is essential for both β-oxidation and lipid synthesis. Its role is to commit FAs intracellularly in response to the bioenergetic demands of the cell.

Drs Padanad, Scaglioni, and colleagues found that mutant KRAS upregulates ACSL3 in lung cancer cells, both in vitro and in vivo. The suppression of ACSL3 decreases β-oxidation, leading to lower adenosine triphosphate (ATP) levels, and subsequent cell death. Like mutant KRAS expression, ACLS3 was also found to be required for tumorigenesis and for tumor maintenance.

As mutant KRAS is 1 of the most prevalent proto-oncogenes, these developments are clinically promising. In the field of cancer metabolism, the focus was previously on glucose and glutamine aberrations, as insights into the mechanism(s) of mutant KRAS' effect remained evasive.

While approximately 30% of NSCLC tumors are affected by mutant KRAS, the mutation is implicated in up to 50% of colorectal cancers and over 90% of pancreatic cancers. Mutant KRAS tumors are also linked to a poor prognosis, particularly due to their resistance to epidermal growth factor receptor inhibitors. The development of alternative treatments is therefore imperative.

Left: Mahesh Padanad, PhD - postdoctoral research fellow at UT Southwestern (first author)
Right: Pier Scaglioni, MD - associate professor at UT Southwestern (PI)

The authors of the present study are screening options for small molecule inhibitors of ACLS3. In an interview with Cancer Therapy Advisor, Dr Scaglioni, associate professor at the University of Texas Southwestern Medical Center (UT Southwestern) in Dallas, discussed the obstacles researchers face moving forward: “The study of lipids has been difficult because the analytic platforms to analyze complex lipid mixtures in a quantitative manner are not fully developed. Many aspects of fatty acid metabolism are unknown, because mass spectrometry techniques to detect individual lipid species are not as developed as the techniques used to detect aqueous metabolites. This is an entire field that needs to be studied.”

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters